GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » 5-Year ROIIC %

Astellas Pharma (Astellas Pharma) 5-Year ROIIC % : -10.11% (As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Astellas Pharma's 5-Year ROIIC % for the quarter that ended in Mar. 2023 was -10.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Astellas Pharma's 5-Year ROIIC % or its related term are showing as below:

ALPMY's 5-Year ROIIC % is ranked worse than
73.05% of 998 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs ALPMY: -10.11

Astellas Pharma 5-Year ROIIC % Historical Data

The historical data trend for Astellas Pharma's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma 5-Year ROIIC % Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.53 6.45 -11.42 -15.03 -10.11

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -10.11 - - -

Competitive Comparison of Astellas Pharma's 5-Year ROIIC %

For the Drug Manufacturers - General subindustry, Astellas Pharma's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's 5-Year ROIIC % falls into.



Astellas Pharma 5-Year ROIIC % Calculation

Astellas Pharma's 5-Year ROIIC % for the quarter that ended in Mar. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( 734.0417172 (Mar. 2023) - 1535.519 (Mar. 2018) )/( 14867.283 (Mar. 2023) - 12700.657 (Mar. 2018) )
=-801.4772828/2166.626
=-36.99%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Astellas Pharma  (OTCPK:ALPMY) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Astellas Pharma 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines

From GuruFocus